Home
    Disclaimer
    ← Back to 6-APDB
    6-APDB molecular structure

    6-APDB Stats & Data

    Psychedelic Stimulant Empathogen Research-chemical
    Ema-3 4-desoxy-mda
    PubChem CID 192599
    NPS DataHub
    MW177.25
    FormulaC11H15NO
    CAS152623-93-3
    IUPAC1-(2,3-dihydro-1-benzofuran-6-yl)propan-2-amine
    SMILESCC(N)Cc1ccc2CCOc2c1
    InChIKeyVRNGXHJGMCJRSQ-UHFFFAOYSA-N
    Phenethylamines; Arylalkylamines; 2020/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2021/1. Von 2-Phenethylamin abgeleitete Verbindungen; 2022/1. Von 2-Phenethylamin abgeleitete Verbindungen
    Chemical Class Amphetamine
    Psychoactive Class Psychedelic / Stimulant

    Pharmacology

    DrugBank

    Receptor Profile

    Receptor Actions

    Inhibitors
    Serotonin-dopamine-norepinephrine reuptake inhibitor (SNDRI)
    Other
    Serotonin-dopamine-norepinephrine releasing agent (SNDRA)

    Toxicity

    PsychonautWiki

    Due to only having a short history of human use, the toxicity and harm potential is not exactly known. Due to its similarity to MDMA, it is likely that the administration of repeated or high dosages of 6-APDB can be neurotoxic and cardiotoxic in some form. The exact toxic dosage is unknown. It is strongly recommended that one use harm reduction practices when using this drug.

    Effect Profile

    Curated + 2 Reports
    Psychedelic 6.1

    Strong visuals and auditory effects with mild body load, low headspace

    Visual Intensity×3
    10
    Headspace Depth×3
    1
    Auditory Effects×1
    10
    Body Load / Somatic Effects×1
    4
    Empathogen 8.7

    Strong euphoria, sensory enhancement, and empathy with moderate stimulation

    Empathy / Social Openness×3
    8
    Euphoria / Mood Elevation×2
    10
    Stimulation×1
    7
    Sensory Enhancement×1
    10
    Stimulant 7.0

    Strong euphoria and anxiety/jitters with moderate stimulation and focus

    Stimulation / Energy×3
    7
    Euphoria / Mood Lift×2
    10
    Focus / Productivity×2
    7
    Anxiety / Jitters×1
    9
    Based on reports from:
    Bluelight Big & Dandy Thread Erowid Experience Reports PsychonautWiki 6-APDB

    Tolerance & Pharmacokinetics

    drugs.wiki

    Tolerance Decay

    Full tolerance 1d Half tolerance 30d Baseline ~90d

    Experience Report Analysis

    Erowid
    2 Reports
    2013–2014 Date Range
    2 With Age Data

    Demographics

    Gender Distribution

    Age Distribution

    Reports Over Time

    Read full reports on Erowid →

    Legal Status

    Country Status Notes
    Canada 6-APDB is Schedule III in Canada as it is an analogue of MDA. The CDSA was updated as a result of the Safe Streets Act changing amphetamines from Schedule 3 to Schedule 1.
    France 6-APDB is classified as a narcotic since May 9, 2018, alongside other substances derived from benzofuran.
    Germany 6-APDB is controlled under the NpSG ( New Psychoactive Substances Act ) as of November 26, 2016. Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized.
    Italy 6-APDB is a prohibited substance in Italy.
    Sweden 6-APDB is prohibited in Sweden as a "health hazard" as of 2009.
    Switzerland 6-APDB is a controlled substance specifically named under Verzeichnis E.
    United Kingdom 6-APDB is a class B drug in the United Kingdom since June 10, 2013. It is banned by a blanket law on benzofurans and related compounds.
    United States 6-APDB is unscheduled in the United States. It may be considered an analog of MDA (which is a Schedule I drug under the Controlled Substances Act). As such, the sale and possession for the purposes of human consumption or could be prosecuted as crimes under the Federal Analog Act.

    References

    Data Sources

    Cited References

    ← Back to 6-APDB